A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Financial Summary
| Share Statistics | LNAI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.8 | $252.6 | 6% |
|
| Shares Out (Mil) | 3.1 | 52.3 | 10% |
|
| Institutional Ownership | 9.2% | 92.1% | 7% |
|
| Float (Mil) | 2.9 | 40.2 | 7% |
|
| Beta | 0.35 | 0.95 | 20% |
|
| Avg Daily Volume (000s) | 25 | 455 | 22% |
|
| Price Change (52-week) |
(91.3%) | 52.9% | 4% |
|
| Growth | LNAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (73.3%) | (9.9%) | 4% |
|
| EPS (5yr) | (34.3%) | 16.0% | 6 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 60.4% | (15.6%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LNAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($128) | ($43) | 9% |
|
| EPS (TTM) | ($46.208) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($31) | 24% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $5 | 49% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 10% |
|
| Enterprise Value (Q1) (Mil) | $9 | $180 | 7% |
|
| Valuation | LNAI | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | LNAI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (201.1%) | (49.8%) | 2% |
|
| ROE | (325.5%) | (55.5%) | 2% |
|
| Liabilities to Assets | 196.9% | 30.3% | 99% |
|
| F-Score | 3 | 3 | 19% |
|
Lunai Bioworks Inc. did not pass any screens on 7/31/2026.
